Welcome to our dedicated page for Connect Biopharma Holdings American Depositary Shares news (Ticker: CNTB), a resource for investors and traders seeking the latest updates and insights on Connect Biopharma Holdings American Depositary Shares stock.
Connect Biopharma Holdings Limited (Nasdaq: CNTB) is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases. The company is headquartered in Taicang, China, and has a significant presence in San Diego, CA. Connect Biopharma leverages its expertise in T cell biology to develop next-generation immune modulators for treating serious autoimmune diseases and inflammation.
Connect Biopharma's core business revolves around the discovery and development of small molecules and antibodies targeting critical pathways of inflammation. The company has built a robust portfolio of drug candidates, including:
- Rademikibart (CBP-201): An antibody targeting interleukin-4 receptor alpha (IL-4Rα), developed for treating atopic dermatitis (AD) and asthma.
- Icanbelimod (CBP-307): A modulator of S1P1 T cell receptors, designed for the treatment of ulcerative colitis (UC).
- CBP-174: An investigational antagonist of histamine receptor 3, aimed at managing pruritus associated with AD.
Recent achievements include a strategic partnership with Simcere Pharmaceutical Co., Ltd. for the development and commercialization of rademikibart in Greater China. This collaboration includes an upfront payment of ¥150 million RMB (approximately US$21 million) and potential milestone payments up to ¥875 million RMB (approximately US$120 million), along with royalties.
Connect Biopharma’s financial condition is supported by its ongoing clinical trials and strategic partnerships. The company aims to complete rademikibart’s clinical trials for AD in China by the end of Q1 2024, with a new drug application submission planned thereafter.
The company has a deep commitment to leveraging functional T cell assays to screen and discover potent product candidates, aiming to provide innovative treatments for patients suffering from autoimmune and inflammatory diseases worldwide. For more information, visit Connect Biopharma.
Connect Biopharma Holdings Limited (Nasdaq: CNTB) has appointed Mr. Steven Chan as Chief Financial Officer, effective November 22, 2021. Chan brings over 25 years of financial expertise from various sectors, including healthcare and biotechnology. He succeeds Eric Hall, who served as Interim CFO. Chan's experience includes leadership roles in notable companies like Arcus Biosciences and Myokardia. He expressed enthusiasm for leading the finance function at Connect, highlighting potential for growth following the company's recent IPO and progress in its innovative pipeline.
Connect Biopharma (Nasdaq: CNTB) has officially completed enrollment in its Phase 2 clinical trial for CBP-307, a treatment for moderate-to-severe ulcerative colitis, involving 134 patients. This trial, which takes place over 12 weeks, includes an induction phase followed by a maintenance phase for responders. CEO Zheng Wei expressed optimism about CBP-307's potential to fill an unmet need in UC therapies. Topline results are expected by the end of Q1 2022, building on promising Phase 1 findings showcasing its safety and T cell modulation effects.
Connect Biopharma reported positive topline results from its global Phase 2 trial of CBP-201 for adult patients with moderate-to-severe atopic dermatitis. The trial met its primary endpoint, showing statistically significant Eczema Area and Severity Index (EASI) score reductions across all treatment arms compared to placebo. Key secondary endpoints also demonstrated efficacy. CBP-201 exhibited a favorable safety profile with low incidence of adverse events. The Company plans to initiate a Phase 3 trial program in mid-2022 to further explore the therapeutic potential of CBP-201.
Connect Biopharma Holdings Limited (Nasdaq: CNTB) announced that CEO Dr. Zheng Wei and Chief Business Officer Dr. Selwyn Ho will participate in fireside chats at two healthcare conferences.
- Jefferies London Healthcare Conference: Available on-demand from November 18 at 8:00 a.m. GMT.
- 33rd Annual Piper Sandler Healthcare Conference: Available on-demand from November 22 at 10:00 a.m. ET.
Webcasts will be accessible on the Company’s Investor Relations page. Connect Biopharma focuses on therapies for chronic inflammatory diseases, with product candidates targeting conditions like atopic dermatitis and ulcerative colitis.
Connect Biopharma Holdings Limited (Nasdaq: CNTB) announced that Dr. Zheng Wei, CEO, and Dr. Selwyn Ho, Chief Business Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on October 26, 2021, at 1:00 PM ET. A webcast of the discussion will be available on the Company's Investor Relations page, with a replay accessible afterward. Connect Biopharma focuses on developing therapies for chronic inflammatory diseases, with lead candidates CBP-201 and CBP-307 currently in clinical trials for conditions like atopic dermatitis and ulcerative colitis.
Connect Biopharma (Nasdaq: CNTB) announced the dosing of the first subject in a Phase 2 trial for CBP-201, targeting chronic rhinosinusitis with nasal polyps (CRSwNP). This randomized, double-blind, placebo-controlled trial aims to evaluate the efficacy of CBP-201 in reducing nasal polyp scores and congestion in patients inadequately controlled by current therapies. The study enrolls approximately 140 subjects across 60 sites globally. CBP-201 targets interleukin-4 receptor alpha and has shown promise in earlier trials for various inflammatory diseases.
Connect Biopharma (Nasdaq: CNTB) has initiated a pivotal trial in China for its drug CBP-201, targeting adults with moderate-to-severe atopic dermatitis. This multicenter, randomized trial will evaluate CBP-201's efficacy and safety, enrolling approximately 255 patients across 55 clinical sites. The trial involves a 16-week treatment phase followed by a 36-week maintenance period. Atopic dermatitis is increasingly prevalent in China, highlighting the need for effective treatments. Success in this trial could expedite patient access to CBP-201.
Connect Biopharma reported a net loss of RMB 942.5 million (USD 145.9 million) for H1 2021, a significant increase from RMB 75.2 million in the same period last year. The company completed its IPO in March 2021, raising approximately USD 204.5 million, boosting cash to RMB 2,025 million (USD 313.5 million). Key milestones include the completion of Phase 2 trials for CBP-201 in atopic dermatitis and asthma, with top-line data expected in Q4 2021. R&D expenses surged to RMB 217.8 million (USD 33.7 million), driven by increased clinical and personnel costs.
Connect Biopharma (Nasdaq: CNTB) announced it will report financial results for H1 ended June 30, 2021 after market close on August 31, 2021. A webcast and conference call to discuss the results will take place on September 1, 2021, at 8:30 am ET. The company is advancing therapies for chronic inflammatory diseases through T cell research. Their lead product candidates include CBP-201 for atopic dermatitis and asthma, and CBP-307 for ulcerative colitis and Crohn’s disease. For more details, refer to their website.
Connect Biopharma (Nasdaq: CNTB) has appointed Jiang Bian as General Counsel & Chief Compliance Officer, effective August 20, 2021. Bian brings extensive experience from Guardant Health and Pieris Pharmaceuticals, focusing on legal issues in healthcare and biopharma. Additionally, Jean Liu has joined the Board of Directors as an Independent Director, contributing over 20 years of biotech experience. These appointments aim to strengthen executive leadership and support Connect Biopharma's growth strategy, particularly in developing therapies for chronic inflammatory diseases.
FAQ
What is the current stock price of Connect Biopharma Holdings American Depositary Shares (CNTB)?
What is the market cap of Connect Biopharma Holdings American Depositary Shares (CNTB)?
What is Connect Biopharma Holdings Limited?
What are Connect Biopharma's key drug candidates?
Where is Connect Biopharma headquartered?
What is the latest news about Connect Biopharma?
What are the financial terms of the partnership with Simcere?
What are the current projects of Connect Biopharma?
How does Connect Biopharma discover new drug candidates?
What diseases is Connect Biopharma targeting?
Who are the key partners of Connect Biopharma?
Where can I find more information about Connect Biopharma?
